BioSight closes investment from Arkin, Primera


Closely-held BioSight has closed an investment of $13-million led by Mori Arkin’s pharmaceutical investment firm, Arkin Holdings, and the U.S.-based venture firm, Primera Capital.

Proceeds will be used for a multi-center, Phase 2b clinical trial with the company’s lead product, Astarabine, for the treatment of acute myeloid leukemia (AML).

Under the accord, Arkin Holdings and Primera will invest $5-million each, and an additional $3-million will come from existing shareholders, including Michael Ilan Management & Investments.

BioSight is currently completing a Phase 1/2a clinical trial to evaluate the safety and efficacy of Astarabine as a monotherapy for AML and acute lymphoblastic leukemia (ALL) at Rambam Hospital in Israel.

Results obtained to date indicate a good safety profile with no significant drug-related side effects, including in 80-and 90-year-old patients. In addition, Astarabine treatment achieved high response rates in newly diagnosed AML/ALL and secondary AML patients unfit for conventional chemotherapy.

BioSight is preparing a multi-center Phase 2b trial in the U.S., Europe, and Israel, to further evaluate the efficacy and safety of Astarabine in the treatment of AML.


Sign up to our weekly BioTuesdays newsletter.